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Blunting autoreactivity without compromising immu-
nity remains an elusive goal in the treatment of auto-
immunity. We show that progression to autoimmune
diabetes results in the conversion of naive low-
avidity autoreactive CD8+ T cells into memory-like
autoregulatory cells that can be expanded in vivo
with nanoparticles coated with disease-relevant
peptide-major histocompatibility complexes (pMHC-
NP). Treatment of NOD mice with monospecific
pMHC-NPs expanded cognate autoregulatory
T cells, suppressed the recruitment of noncognate
specificities, prevented disease in prediabetic mice,
and restored normoglycemia in diabetic animals.
pMHC-NP therapy was inconsequential in mice engi-
neered tobear an immunesystemunresponsive to the
corresponding epitope, owing to absence of epitope-
experienced autoregulatory T cells. pMHC-NP-
expanded autoregulatory T cells suppressed local
presentation of autoantigens in an interferon-g-, indo-
leamine 2,3-dioxygenase-, and perforin-dependent
manner. Nanoparticles coated with human diabetes-
relevant pHLA complexes restored normoglycemia
in a humanized model of diabetes. These observa-
tions expose a paradigm in the pathogenesis of auto-
immunity amenable for therapeutic intervention.
INTRODUCTION
Spontaneous autoimmune disorders typically result from poly-
clonal immune responses against many antigens. Although non-
antigen-specific, mAb-based immunosuppressive approaches
have shown benefit in clinical trials (Kaufman and Herold, 2009),
these strategies bear the inherent risk of compromising immunity
to infections and cancer.
Type 1 diabetes (T1D) in both humans and nonobese diabetic
(NOD) mice is a chronic autoimmune disease that results from568 Immunity 32, 568–580, April 23, 2010 ª2010 Elsevier Inc.destruction of pancreatic b cells by CD4+ and CD8+ T cells
targeting many antigens (Lieberman and DiLorenzo, 2003; Tsai
et al., 2008). A large fraction of the islet-associated CD8+ cells
in NOD mice recognize the mimotopes NRP-A7 and -V7 in the
context of the MHC molecule Kd (Verdaguer et al., 1996, 1997;
Anderson et al., 1999). These T cells are diabetogenic (Verda-
guer et al., 1997), target a peptide from islet-specific glucose-
6-phosphatase catalytic subunit-related protein (IGRP206-214,
similar to NRP-A7 and -V7) (Lieberman et al., 2003), and circulate
in the blood, particularly as clinical disease nears (Trudeau et al.,
2003). Another important feature of the diabetogenic CD8+
response is that it involves recognition, by smaller T cell pools,
of many other IGRP epitopes (Han et al., 2005a) and epitopes
in other, even ubiquitous, autoantigens, such as dystrophia
myotonica kinase (DMK) (Lieberman et al., 2004). The polyspeci-
ficity of this T cell response is compounded by the fact that indi-
vidual specificities harbor clones engaging pMHC over a range
of avidities, the strength of which correlates with pathogenic
potential (Amrani et al., 2000).
This complexity is a barrier to the design of therapeutic
strategies that selectively purge the immune system of autoreac-
tivity without impairing systemic immunity. Soluble peptides
can induce peptide-specific T cell tolerance (Aichele et al.,
1994) but cannot blunt polyspecific autoimmune responses,
unless they target key disease-triggering autoantigen(s) and are
administered before other autoantigenic specificities become
involved. Unfortunately, this situation only applies to the earliest
stages of disease. For example, despite effectively deleting
the IGRP206-214-reactive CD8
+ pool, NRP-V7 therapy did not
protect NOD mice from T1D because it fostered occupation of
the voided intraislet ‘‘niche’’ by CD8+ cells recognizing other
epitopes (Han et al., 2005a). This suggested that therapeutic
successmight require deletion of multiple antigenic specificities.
Because peptides are more tolerogenic when bound to MHC
molecules on costimulation-impaired APCs than when used in
solution (Miller et al., 1979), we envisioned that simultaneous
delivery of several different T1D-relevant peptide-MHC (pMHC)
complexes by nanoparticles (NPs) would enable the type of
combinatorial autoantigen therapy needed to blunt T1D.
Unexpectedly, we found that monospecific pMHC-NP therapy
was able to both blunt T1D progression in prediabetic mice and
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Most surprisingly, we found that pMHC-NP therapy functions
by expanding, in an epitope-specific manner, a subset of
antigen-experienced autoreactive CD8+ cells that suppresses
the activation and recruitment of noncognate specificities to
islets. These memory-like ‘‘autoregulatory’’ CD8+ cells arise
spontaneously (during disease—prior to pMHC-NP therapy—
and within different autoantigen-specific T cell pools) from
nonpathogenic low-avidity clones and blunt the recruitment of
other specificities by suppressing presentation of autoantigens
in the pancreas-draining lymph nodes. Because these pools of
protective antigen-experienced CD8+ cells are not limited to
specific epitopes or autoantigens and arise only in affected,
but not healthy, individuals, NPs coated with any disease-rele-
vant pMHC complex have the potential to become powerful
vaccines capable of blunting and resolving polyclonal autoim-
mune responses in a disease-specific manner.
RESULTS
pMHC-NPs Blunt T1D while Expanding Cognate
Low-Avidity Autoreactive T Cells
To ascertain if pMHC-NPs could delete cognate CD8+ cells, we
treated NRP-V7 (IGRP206-214)-reactive 17.4a-8.3b-TCR-trans-
genic NOD mice (Verdaguer et al., 1997) with NRP-V7-Kd-NPs
(Moore et al., 2004). The naive CD8+ cells of these mice were
gradually deleted, and those escaping deletion showed reduced
recall proliferation in vitro (Figures S1A and S1B).
Since T1D in wild-type NOD mice involves many antigenic
specificities, we reasoned that prevention of disease might
require the use of pools of NPs coated with different pMHCs.
Because 40% of islet CD8+ cells recognize epitopes from
IGRP (Han et al., 2005a), we synthesized pMHC-coated NPs
(pMHC-NP) targeting the six most prevalent pools of IGRP-
specific CD8+ cells. We treated young NOD mice (every 2 to
3 weeks) with a mixture of these six pMHC-NP types or with
control NP (carrying biotin or a T1D-irrelevant pMHC [TUM-Kd]).
Mice treated with the NP pool, unlike those receiving control NP,
were 100% protected from T1D (data not shown). As an addi-
tional control, we used NRP-V7-Kd-NPs alone, which were ex-
pected to delete the entire IGRP206-214-reactive pool without
blunting T1D progression.
Unexpectedly, NRP-V7-Kd-NPs protected mice from T1D
(Figure 1A), but not insulitis (Figure 1B). Most surprisingly, these
mice had significantly larger pools of circulating and intra-islet
NRP-V7-Kd tetramer+ CD8+ cells versus control NP-treated or
untreated animals (p < 0.05; Figures 1C and 1D). Similar results
were obtained with NP coated with IGRP206-214-K
d (Figure 1A).
Comparison of mice that had progressed to diabetes versus
those that did not suggested an association between the anti-
T1D effect of NRP-V7-Kd-NP and expansion of cognate CD8+
cells (Figure 1E). Furthermore, these T cell-expanding and anti-
T1D effects were dose dependent (Figures S1C and S1D) and
cumulative (Figure S1E). Additional studies showed that these
NPs are taken up by cognate T cells without accumulating in
CD11b+, CD11c+, or B cells (Figures S1F and S1G).
Because the islets of young prediabetic NOD mice are
enriched for low-avidity autoreactive CD8+ clones (Amrani
et al., 2000) and these clones appear to slow down the diabeto-genic process (Amrani et al., 2000; Han et al., 2005a), we asked if
the cells that had expanded in response to pMHC-NP therapy
belonged to this low-avidity subset. Indeed, the intraislet NRP-
V7-Kd tetramer+ CD8+ cells of NRP-V7-Kd-NP-treated mice
bound pMHC with significantly lower avidity (>Kd) than those
of control mice (p = 0.01;Figure 1F). Furthermore, treatment
with NRP-V7-Kd-NPs induced changes in the TCRa repertoire
of islet-associated NRP-V7-Kd-tetramer+ cells, consistent with
enrichment for low-avidity clones, expressing Va17.6-Ja42
chains using noncanonical CDR3a sequences (other than
MRD-E) (Figure 1G).
We next wondered if the T cell-expanding and anti-T1D effects
of pMHC-NPwere a peculiarity of NRP-V7-Kd or IGRP206-214-K
d.
We treated NOD mice with NP coated with Db presenting a
mimotope for DMK138-146 (MimA2), which is targeted by a
much smaller subset of CD8+ cells (Lieberman et al., 2004).
MimA2-Db-NPs expanded the circulating and intraislet MimA2-
Db+ CD8+ pools several fold, in this case from virtually undetect-
able levels (Figures 1H and 1I), and afforded T1D protection
(Figure 1J). Comparative measurements of avidity were not
possible here because the size of the MimA2-reactive subset
in islets of untreated NOD mice is too small (Figure 1I). Impor-
tantly, T cell expansion by these two different types of pMHC-
NP was antigen specific (Figures S1H–S1J).
We then asked if enhanced recruitment of pMHC-NP-
expanded CD8+ cells impaired the recruitment of other autor-
eactive CD8+ cells. We compared the responsiveness of the
islet-derived CD8+ cells of mice treated with control and NRP-
V7-Kd- or MimA2-Db-NP to a panel of 76 different IGRP epitopes
(Han et al., 2005a). Islet-associated T cells were short-term
expanded using an approach that does not significantly alter
the relative distribution of autoreactive specificities as found
in uncultured islets (Figures S1K and S1L). As shown in
Figure 1K, pMHC-NP-treated mice recruited substantially fewer
CD8+ specificities than control mice. Thus, NPs coated with
T1D-relevant pMHCs blunt the recruitment of noncognate
T cell specificities and T1D by expanding cognate low-avidity
autoreactive CD8+ T cells.
pMHC-NP Therapy Restores Normoglycemia in Diabetic
NOD Mice
To investigate if monospecific pMHC-NP therapy could restore
normoglycemia in diabetic mice, we randomized newly diabetic
animals into treatment with TUM-Kd-NP (control), NRP-V7-Kd-
NP, or MimA2-Db-NP. All mice received two weekly doses of
NP and were monitored twice a week for blood glucose. An
additional cohort was treated with NRP-V7-Kd tetramers, using
amounts of pMHC similar to those given when coated onto
NPs. Treatment with CD3 mAb was used as a positive control.
Unlike mice treated with TUM-Kd-NP or pMHC tetramers,
most (>75%) NRP-V7-Kd-NP- and MimA2-Db-NP-treated mice
became normoglycemic (Figures 2A and 2B and Figure S2D)
and displayed large increases in the peripheral frequency of
tetramer+ CD8+ cells (Figures S2A and S2B). No differences in
the peripheral frequency FoxP3+CD4+ Treg cells were observed
(Figure S2C). Four of sixmice treatedwithCD3mAbalso became
normoglycemic (Figure S2D). Thus, theNPcomponent of pMHC-
NPs is essential, and the effectiveness of the pMHC-NP
approach is comparable to that of CD3 mAb. HistopathologicalImmunity 32, 568–580, April 23, 2010 ª2010 Elsevier Inc. 569
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Figure 1. pMHC-NPs Expand Low-Avidity Autoreactive CD8+ Cells and Protect NOD Mice from Diabetes
(A) NODmice were left untreated (n = 65) or injected i.v. with 7.5 mg of NRP-V7-Kd-NP (n = 21) IGRP206-214-K
d-NP (n = 10) or control NP (TUM-Kd- [n = 15] or biotin-
coated NP [n = 10]) at 4, 6, and 8 weeks and every 3 weeks until the 32nd week. p values are versus the NRP-V7-Kd-NP group.
(B) Insulitis scores in nondiabetic mice at 32 weeks (pMHC-NP-treated, n = 4; untreated, n = 3).
(C) NRP-V7-Kd-NP expanded NRP-V7-Kd tetramer+ CD8+ cells in blood (n = 14) and enhanced their recruitment to islets (n = 11) versus control-NP-treated mice
(n = 4 and 21, for blood and islets, respectively). Data correspond to percent tetramer+ cells (± SEM) within the CD8+ gate. Islet-associated CD8+ cells were from
individual mice.
(D) Representative tetramer stains for islet-derived CD8+ cells of NRP-V7-Kd-NP-treated mice.
(E) Only protected, but not diabetic, NRP-V7-Kd-NP-treated NOD mice had expanded pools of NRP-V7-Kd-tetramer+ cells in blood (n = 10 and 4, respectively).
(F) The islet-associated CD8+ cells of NRP-V7-Kd-NP-treated mice (n = 5) bound pMHC with lower avidity than those from untreated age-matched NOD mice
(n = 11).
(G) TCRa repertoire of NRP-V7-Kd-tetramer+ cells from untreated 9- and 20-week-old NOD mice and 15 week-old NOD mice that had either been treated for
5 weeks with NRP-V7-Kd-NP starting at 10 weeks of age or left untreated. Data correspond to 57-58 cDNA clones/group from two independent experiments.
HA, high-avidity; LA, low-avidity, as defined by comparing the TCR repertoires of the LA pools of 9-week-old NOD mice and the HA pools of 20-week-old
NOD mice (Han et al., 2005b). In MRx, x corresponds to any amino acid other than D or E.
(H) MimA2-Db-NP expandMimA2-Db tetramer+ CD8+ cells in blood (n = 11) and islets (n = 13) versus controls (n = 4 and 3). Data correspond to nondiabeticmice at
the end of follow-up.
(I) Representative tetramer stains for islet-derived CD8+ cells of untreated and MimA2-Db-NP-treated mice.
(J) Disease curves for MimA2-Db-NP-treated (n = 18) versus control groups (control-NP, n = 25; untreated, n = 65).
(K) Islet-associated CD8+ cells from control-NP-treated (n = 9), NRP-V7-Kd-NP-treated (n = 5), and MimA2-Db-NP-treated (n = 4) mice were assayed for IFNg
production in response to splenocytes pulsed with each of 76 different IGRP epitopes or the negative control TUM, and the number of positive responses
(>50 pg/ml) was counted. Panel displays the percent of peptides that elicited positive responses in CD8+ cells from individual mice (mean ± SEM).
See also Figure S1.
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Figure 2. NRP-V7-Kd- and MimA2-Db-NP Restore Normoglycemia in Diabetic NOD Mice by Expanding Memory-like Antidiabetogenic CD8+
T Cells
(A) Average blood glucose/group (includes diabetic and nondiabetic mice; the average nonfasting blood glucose levels in the ‘‘cured’’ mice were <8 mM and
similar to nondiabetic untreated mice). NOD mice with > 11 mM of blood glucose were treated with NRP-V7-Kd tetramers (n = 5), TUM-Kd-NP (n = 9), NRP-
V7-Kd-NP (n = 11), or MimA2-Db-NP (n = 11) (until normoglycemic for 4 weeks).
(B) Disease incidence curves.
(C) Insulitis scores in nondiabetic untreated 50-week-old mice (n = 6) at the onset of diabetes prior to the initiation of treatment (n = 3; 16–22 weeks) and after
restoration of normoglycemia (50 weeks; n = 5). The scores were 1.93 ± 0.39, 2.42 ± 0.12, and 0.64 ± 0.16, respectively.
(D) Representative flow cytometry profiles of tetramer+ and tetramer CD8+ cells from NRP-V7-Kd-NP-treated mice.
(E) Sorted pMHC-NP-expanded tetramer+ CD8+ cells secrete IFN-g but do not produce IL-2 or proliferate in response to peptide-pulsed DCs.
(F) In vitro suppression of 17.4a-8.3b-CD8+ proliferation by pMHC-NP-expanded NRP-V7-Kd or MimA2-Db tetramer+CD8+ cells (in response to NRP-V7- [left]
or NRP-V7+MimA2-pulsed DCs [right]).
(G) Proliferation of CFSE-labeled 17.4a-8.3b-CD8+ cells in the MLN, PLN, and spleen of untreated age-matched NOD mice or MimA2-Db-NP-cured mice
(at 35 weeks). Data correspond to five and three mice, respectively.
(H) Left: MimA2-Db-NP-expanded CD8+ cells from cured NOD mice (n = 6; 5 3 106 CD8+ cells, containing < 5 3 104 MimA2-Db tetramer+ cells) suppress the
adoptive transfer of diabetes by splenic T cells from prediabetic NOD mice into NOD.scid females compared to total CD4+ cells (5 3 106) from cured donors
(n = 6). Right: NRP-V7-Kd-NP treatment (twice/week) potentiates the transfer of protection by splenic CD8+ cells from NRP-V7-Kd-NP-cured mice into T cell-
reconstituted NOD.scid hosts (n = 3) but cannot induce protective activity in splenic CD8+ T cells from untreated NOD donors (n = 4).
See also Figure S2.
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percentages of noninfiltrated islets, compared to age-matched
nondiabetic untreated mice and mice immediately before treat-
ment (Figure 2C and Figure S2E). Withdrawal of therapy after 4
weeks of normoglycemia resulted in a progressive decline in
the size of the circulating tetramer+ pool (Figure S2B) and a
40%–50% recurrence rate within 20 weeks (Figures S2D andS2F), suggesting that the protective effects of pMHC-NP wane
without boosting. Weight assessments, intraperitoneal glucose
tolerance tests, and serum insulin measurements confirmed
that pMHC-NP therapy restored the insulin secretory capacity
of the pancreas (Figures S2G–S2J). Thus, when initiated shortly
after onset of hyperglycemia, pMHC-NP therapy protects b cells
from further attack, enabling functional recovery.Immunity 32, 568–580, April 23, 2010 ª2010 Elsevier Inc. 571
Immunity
Boosting Autoregulatory T Cells with pMHC-NPThe pMHC-NP-Expanded Low-Avidity CD8+ Cells
Are Memory-like and Regulatory
The tetramer+ cells of NRP-V7-Kd- and MimA2-Db-NP-treated
mice were FoxP3, CD69, and CD25 (data not shown) but
enriched for cells expressing the memory markers CD44 and
CD122. These memory-like CD44hiCD122+CD8+ cells were
CCR7, CXCR3+, andCD62Lhi (Figure 2D), a phenotype different
from that of classical central and effector memory T cells
(Sallusto et al., 2004) or the CD122+CD8+ Treg subset described
in healthy strains (Endharti et al., 2005). Like conventional
memory T cells, these CD8+ cells produced high amounts of
IFN-g in response to antigen-pulsed DCs (Figure 2E). However,
unlike naive and conventional memory CD8+ cells, they neither
secreted IL-2 nor proliferated (Figure 2E).
In vitro, these pMHC-NP-expanded T cells suppressed the
proliferation of CFSE-labeled 17.4a-8.3b-CD8+ cells in response
to peptide-pulsed DCs (Figure 2F and Figure S2K). Suppression
was antigen nonspecific because theMimA2-Db tetramer+ CD8+
cells of MimA2-Db-NP-treated mice could suppress the prolifer-
ation of CFSE-labeled NRP-V7-Kd-specific 17.4a-8.3b-CD8+
cells to DCs pulsed with both MimA2 plus NRP-V7 (Figure 2F).
These pMHC-expanded cells also had regulatory activity
in vivo. Thus, the PLNs of MimA2-Db-NP-treated NOD mice,
unlike those from untreated age-matched controls, could not
support the proliferation of naive CFSE-labeled 17.4a-8.3b-
CD8+ cells (Figure 2G). Furthermore, splenic CD8+ (but not
CD4+) cells from pMHC-NP-cured mice inhibited the transfer
of diabetes by wild-type NOD splenic T cells into NOD.scid
recipients (Figure 2H). In addition, pMHC-NP treatment of the
hosts enhanced the anti-T1D properties of CD8+ cells from
pMHC-cured mice without eliciting antidiabetogenic activity in
CD8+ cells from untreated NOD donors (Figure 2H). Thus, the
CD8+ T cells that expand in response to pMHC-NP therapy are
memory like and regulatory.
pMHC-NPs Operate via Disease-Generated
Autoregulatory CD8+ Cells
As noted above, pMHC-NP therapy in TCR-TG and wild-type
NOD mice yielded seemingly contradictory results: whereas
pMHC-NP therapy deleted naive autoreactive CD8+ cells in
TCR-TG mice, it expanded low avidity memory-like autoregula-
tory CD8+ cells in NOD mice. Four observations prompted us to
suspect that past autoantigen-experience (i.e., memory) underlie
these differences in responsiveness to pMHC-NP. First, unlike
naive T cells,memory T cells can expand in response to TCR liga-
tionwithout costimulation (Bachmannet al., 1999). Second, treat-
ment of NOD mice with TUM-Kd-NP (a T1D-irrelevant pMHC
complex) did not expand TUM-reactive CD8+ cells (Figure S3A).
Third, the peripheral frequencies of tetramer+CD8+ cells in NRP-
V7-Kd-NP-treated B10.H2g7 mice, which do not develop insulitis
and thus should not contain NRP-V7-Kd-experienced CD8+
clones,weresimilar to thoseseen inuntreatedage-matched litter-
mates (Figure S3B). And fourth, systemic expansion of NRP-V7-
Kd-tetramer+ CD8+ cells in NRP-V7-Kd-NP-treated NOD mice
was more effective when initiated at diabetes onset than in the
prediabetic stage, presumably because the size of the expand-
able memory T cell pool increases with time (Figure S3C).
We thus sought to investigate the consequences of NRP-
V7-Kd- and MimA2-Db-NP treatment in a gene-targeted NOD572 Immunity 32, 568–580, April 23, 2010 ª2010 Elsevier Inc.strain expressing a mutant form of IGRP (encoded in G6pc2) in
which the two TCR-contact residues of IGRP206-214 (Amrani
et al., 2001) are replaced with alanines (K209A and F213A) (Fig-
ure 3A). NOD.G6pc2K209A-F213A mice could not recruit peripheral
IGRP206-214-reactive T cells into islets and thus generate
IGRP206-214-experienced T cells (Figures 3B and 3C). As a result,
treatment of 10-week-old NOD.G6pc2K209A-F213A mice with 10
doses of NRP-V7-Kd-NP over 5 weeks failed to expand NRP-
V7-Kd-reactive CD8+ cells (Figure 3B). Thus, pMHC-NPs only
expand autoantigen-experienced CD8+ cells. We then treated
spontaneously hyperglycemic NOD.G6pc2K209A-F213A mice
with NRP-V7-Kd- or MimA2-Db-NP. Whereas MimA2-Db-NP
expanded the circulating MimA2-Db-reactive CD8+ pool
(Figure 3D) and restored normoglycemia in five of six mice
(Figure 3E and Figrue S3D), treatment with NRP-V7-Kd-NP
neither expanded NRP-V7-Kd-reactive T cells (Figure 3D) nor
restored normoglycemia in the five mice tested (Figure 3E and
Figure S3D). Thus, pMHC-NPs afford diabetes resistance via
disease-induced, autoantigen-experienced CD8+ T cell pools.
‘‘Memory’’ Autoregulatory Cells Arise from Low-Avidity
Precursors
The data suggested that the autoantigen-experienced regulatory
CD8+ cells that expand in response to pMHC-NPs arise from
low-avidity precursors. This hypothesis predicted that low-
avidity autoreactive CD8+ cells maturing in NODmice spontane-
ously differentiate into memory-like autoregulatory T cells. To
test this hypothesis, we cloned an NRP-V7-Kd-reactive TCR
using the 8.3-TCRb chain and a TCRa chain enriched in the
low-avidity CD8+ infiltrates of NRP-V7-Kd-NP-treated NOD
mice (Va17.6-MRD-Ja42) (Figure 1G). This TCRab recognizes
NRP-V7-Kd with 10 times lower affinity (measured by surface
plasmon resonance; L. Teyton and P.Santamaria, unpublished
data) than the 17.4a-8.3b-TCR, which uses the same TCRb but
a slightly different TCRa (enriched in the high-avidity CD8+ infil-
trates of untreated controls [Va17.4-MRD-Ja42]) (Figures 1G).
We refer to these TCRs as 17.6a-8.3b (low-affinity) and 17.4a-
8.3b (high-affinity), respectively.
We compared the developmental biology of these TCRs in
TCR-TGNODmice. Both fostered the development of peripheral
CD8+ repertoires dominated by functional IGRP206-214-reactive
CD8+ cells, albeit with different efficiencies, as expected (Figures
S4A–S4D and data not shown). However, whereas 17.4a-8.3b-
TG mice developed accelerated T1D (versus wild-type NOD
mice) (Verdaguer et al., 1997), 17.6a-8.3b-TG NOD mice were
almost completely resistant to insulitis and T1D, even in mice
unable to rearrange endogenous TCRa chains (Figures S4E–
S4G) and despite harboring fewer CD4+CD25+ Treg cells
(Figure S4H). The T1D resistance of 17.6a-8.3b-TG mice could
not be explained by mere dilution of the endogenous diabeto-
genic T cell repertoire because NOD mice expressing a T1D-
irrelevant TCR developed T1D like NOD mice (Figure S4I) (see
also Serreze et al., 2001).
We next asked if the low- and high-avidity autoreactive CD8+
cells maturing in 17.6a-8.3b- and 17.4a-8.3b-TG NOD mice,
respectively, spontaneously differentiated into memory-like
T cells. The peripheral tetramer+ CD8+ pool of 17.6a-8.3b-
but not 17.4a-8.3b-TG mice, was enriched for CD44hiCD122+
cells, particularly in 17.6a-8.3b-NOD.Tcra/ mice (Figures 4A
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Figure 3. pMHC-NP Operate via Antigen-Experienced T Cells
(A) Schematic diagram comparing G6pc2 (encoding IGRP) from NOD versus NOD.G6pc2K209A-F213A mice.
(B) Percentages of NRP-V7-Kd tetramer+ CD8+ cells in spleen and blood in untreated and NRP-V7-Kd-NP-treated NOD versus NOD.G6pc2K209A-F213A mice
(n = 4–9/mouse type). Mice were treated twice/week with NRP-V7-Kd-NP from the 10th to the 15th week of age.
(C) Representative TUM-Kd, NRP-V7-Kd, and MimA2-Db-tetramer-staining profiles of islet-associated CD8+ cells in diabetic NOD versus NOD.G6pc2K209A-F213A
mice.
(D) Percentages of circulating NRP-V7-Kd or MimA2-Db-tetramer+ CD8+ cells in NRP-V7-Kd-NP- or MimA2-Db-NP-treated NOD versus NOD.G6pc2K209A-F213A
mice, respectively (n = 3–6 samples/mouse type/NP type).
(E) Average blood glucose amounts in NRP-V7-Kd-NP- or MimA2-Db-NP-treated NOD.G6pc2K209A-F213A mice.
See also Figure S3.
Immunity
Boosting Autoregulatory T Cells with pMHC-NPand4B)andproliferatedexvivo in response to IL-2and IL-15 in the
absence of antigen (Figure S4J). These memory-like CD44hi
CD122+CD8+ cells were remarkably similar to those expanded
by pMHC-NPs in NOD mice: FoxP3CD25CCR7CD69
CXCR3+CD62Lhi (Figure 4C and Figures S4L and S4M). Real-
time RT-PCR assays for 384 immunological transcripts
(Figure S4K) and additional FACS analyses (Figure S4L) high-
lighted the memory-like phenotype of these T cells, including
their expression of granzyme B. Furthermore, like the memory-
like CD8+ cells expanded by pMHC-NP, the memory-like CD8+
cells arising in 17.6a-8.3b-TG mice rapidly produced high
amounts of IFN-g, without secreting IL-2 or proliferating, in
response to antigen in vitro (Figure 4D and Figure S4N). Thus,
by and large, these memory-like low-avidity CD8+ cells are iden-
tical inphenotypeand function to those that expand inpMHC-NP-
treated mice.
MemoryCD8+Cells Arising fromLow-Avidity Precursors
Have Regulatory Properties
Unlike their CD122 counterparts or T1D-irrelevant (i.e., LCMV-
gp33-specific) CD8+ cells, the CD122+CD8+ cells of 17.6a-8.3b-TG mice inhibited the proliferation of naive CFSE-labeled CD8+
cells from 17.4a-8.3b-TG mice in response to peptide-pulsed
DCs (Figure 4E). Suppression was not because of competition
for pMHC, because it was not seen when 17.4a-8.3b-CD8+ cells
were used both as responders and suppressors (Figure 4E) and
because it also occurred in assays employing LCMV-gp33-Db-
specific CD8+ cells as responders (Figure S4O). Furthermore,
suppression required a cognate T-APC interaction, because (1)
it did not occur when suppressors and responders were acti-
vated with CD3 and CD28 mAbs in the absence of APCs
(Figure 4E), and (2) it was seen in assays employing DCs pulsed
with a range of NRP-A7 concentrations (1–0.01 mM), but not
when the DCswere only pulsedwith the responder T cells’ ligand
(gp33) (Figure S4O).
Like the memory-like CD8+ cells of pMHC-NP-treated mice,
the memory-like CD8+ cells of 17.6a-8.3b-TG mice blunted the
activation of CFSE-labeled 17.4a-8.3b-CD8+ cells in the PLNs
of prediabetic NODs (Figure 4F). Furthermore, the CD8+ cells
of 17.6a-8.3b-TG mice, but not their CD4+ cells, suppressed
the transfer of diabetes by NOD splenic T cells into NOD.scid
hosts, particularly in those treated with pMHC-NPs (Figures 4GImmunity 32, 568–580, April 23, 2010 ª2010 Elsevier Inc. 573
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Figure 4. Low-Avidity NRP-V7-Kd-Reactive TCR-TG CD8+ Cells Spontaneously Differentiate into Antidiabetogenic Memory-like T Cells
(A) Representative CD44 versus CD122 profiles of splenic CD8+ cells from 17.6a-8.3b- versus 17.4a-8.3b-NOD.Tcra/ mice.
(B) Percentages of CD44hiCD122+CD8+ cells in spleen and PLN of 17.6a-8.3b-NOD versus 17.4a-8.3b-NOD and 17.6a-8.3b-NOD.Tcra/ versus 17.4a-8.3b-
NOD.Tcra/ mice (spleen, n = 4 and 3 and n = 12 and 9, respectively; PLN, n = 4 and 3 and n = 9 and 6, respectively). Mice were 9–18 weeks old.
(C) Phenotypic characteristics. CD8+ cells were stained with CD44, CD122 and CXCR3, CD62L, or CCR7 mAbs.
(D) Secretion of IFN-g and IL-2, and proliferation in response to NRP-A7-pulsed DCs.
(E) Proliferation of CFSE-labeled 17.4a-8.3bCD8+ cells to NRP-A7- and/or LCMV-gp33-pulsedDCs orCD3 or CD28mAbs (without APCs) in the presence of naive
versus memory CD8+ cells from 17.6a-8.3b-, or naive CD8+ cells from 17.4a-8.3b- or LCMV-gp33-specific TCR-TG-NOD mice. r, responders; s, suppressors.
(F) Proliferation of CFSE-labeled 17.4a-8.3b CD8+ cells in the PLN and MLN of wild-type NOD hosts transfused with CD122 versus CD122+ 17.6a-8.3b-CD8+
cells.
(G) Splenic CD8+ cells from 17.6a-8.3b-NOD (n = 10), but not NOD, mice (n = 7) suppress the transfer of diabetes by splenic T cells from NODmice into NOD.scid
recipients. Other cohorts of hosts were transfused with 17.6a-8.3b-CD8+ cells (n = 5) or 17.4a-8.3b-CD8+ cells (n = 4) and then treated with NRP-V7-Kd-NPs.
(H) Suppression of diabetes cannot be transferred with splenic CD4+ cells of NOD (n = 4) or 17.6a-8.3b-NOD mice (n = 7).
See also Figure S4.
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Boosting Autoregulatory T Cells with pMHC-NPand 4H). In contrast, pMHC-NP-treatment did not afford dia-
betes protection to hosts transfused with 17.4a-8.3b-CD8+ cells
(Figure 4G). Thus, pMHC-NPs potentiate the suppressive activity
of autoregulatory T cells but cannot convert a naive autoreactive
T cell into a regulatory one.
IFN-g- and IDO-Dependent Suppression of Antigen
Presentation
Addition of blocking mAbs against IL-10 or TGF-b or an adeno-
sine receptor antagonist (8-PST) had no effect on the in vitro574 Immunity 32, 568–580, April 23, 2010 ª2010 Elsevier Inc.suppressive activity of 17.6a-8.3b-CD44hiCD122+CD8+ cells
(Figure 5A). In contrast, suppression was abrogated in the pres-
ence of an IFN-g mAb (Figure 5A) or the IDO inhibitor 1-methyl-
tryptophan (1-MT). Although necessary, IFN-g was not sufficient
because addition of exogenous IFN-g to peptide-pulsed APCs
did not inhibit their ability to activate 17.4a-8.3b-CD8+ cells.
Similar results were obtained when we used NRP-V7-Kd-
tetramer+ CD8+ T cells from pMHC-NP-treated NOD mice as
suppressors (Figure 5B). Thus, the suppressive activity of autor-
egulatory CD8+ T cells is IFNg and IDO dependent.
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Figure 5. Memory-like Autoregulatory CD8+ Cells Suppress Antigen Presentation via IFNg- and IDO and Kill Antigen-Pulsed APCs via
Perforin
(A) Proliferation of CFSE-labeled 17.4a-8.3b CD8+ cells in response to NRP-A7-pulsed DCs in the absence or presence of memory 17.6a-8.3b-CD8+ cells,
rat-IgG, 1-MT, 8-PST, IFN-g, or blocking mAbs against IL-10, TGFb, or IFN-g. r, responders; s, suppressors.
(B) Anti-IFNg and 1-MT, but not rat-IgG or anti-IL-10, also abrogated the suppressive activity of pMHC-NP-expanded CD8+ cells from NRP-V7-Kd-NP-treated
mice.
(C) The PLNs, but not the MLNs, of NRP-V7-Kd-NP-treated mice contain fewer CD11c+ cells than the PLNs from TUM-Kd-NP-treated mice. Data (shown as
PLN:MLN ratios) correspond to 15-week-old mice treated with two doses of NP/week for 5 weeks. The average percent of CD11c+ cells in the PLNs of each
treatment group are noted below the histograms.
(D) In vivo cytotoxicity assay: NRP-A7- (CFSElo) or TUM-pulsed (CFSEhi) B cell (upper) or splenic DCs (lower) were injected into TCR-TG hosts (1:1). Survival of
transfused APCs in the host spleens was analyzed by FACS 18 hours later.
(E) APC-killing in 17.6a-8.3b-TCR-TG mice is CD8+ and CD122+ T cell-dependent. TUM and NRP-A7-pulsed CFSE-labeled B cells were injected into NOD.scid
mice that had received non-TG or 17.6a-8.3b splenocytes (unsorted or CD8- or CD122-depleted) 24 hr earlier.
(F) NOD mice treated with NRP-V7-Kd- or MimA2-Db-NP kill NRP-V7 or MimA2-pulsed DCs in vivo. Top, representative profiles; bottom, mean ± SEM.
(n = 3/group). Mice received two weekly doses of NP from the 10th to 15th week. Within 48 hr of the last injection, mice were infused with TUM-pulsed
PKH26-labeled or NRP-V7 or MimA2-pulsed CFSE-labeled splenic DCs. DC killing was assessed by comparing the percent of splenic CFSE+ versus PKH26+
cells 18 hr later.
(G) In vivo killing of APCs by 17.6a-8.3b-CD8+CD122+ cells is perforin dependent and Fas independent. CFSE-labeled peptide-pulsed Fas+/+ or Fas/ B cells
were transfused into Prf1+ or Prf1/ TCR-TG hosts, and the spleens were analyzed 18 hr later.
(H) In vivo killing of DCs in NRP-V7-Kd-NP-treated mice is perforin-dependent. Experiments were done as in (F). Top panels show representative profiles. Data in
bottom panel correspond to TUM-Kd-NP versus NRP-V7-Kd-NP-treated Prf1/ NOD mice (n = 5 mice/group).
(I) Proliferation of CFSE-labeled 17.4a-8.3b CD8+ cells in the PLN and MLN of NOD hosts transfused with CD122 versus CD122+ CD8+ T cells from Prf1/
17.6a-8.3b-TCR-TG mice.
See also Figure S5.
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Figure 6. The Anti-T1D Activity of pMHC-NP Also Requires IFN-g, IDO, and Perforin
(A–C) Average blood glucose levels/group (n = 15 for NRP-V7-Kd-NP; n = 5 for pMHC-NP+rat-IgG; n = 6 for pMHC-NP+IFN-gmAb; n = 4 for pMHC-NP+1-MT;
n = 5 and 8 for pMHC-NP in NOD.Ifng/ and NOD.Prf1/, respectively).
(D and E) Proliferation of CFSE-labeled 17.4a-8.3b-CD8+ cells in the PLN andMLN of untreated nondiabetic or acutely diabetic mice (pooled because there were
no differences between the two) andmice from the different groups in (A), except for NOD.Prf1/ hosts, whichwere 15weeks old and treated for 5 weeks starting
at 10 weeks. (D) shows representative flow profiles and (E) quantitative values. Data correspond to eight untreated (four diabetic), three NRP-V7-Kd-NP-treated,
three pMHC-NP+1-MT, three pMHC-NP+IFN-g mAb, and three each of pMHC-NP-treated NOD.Ifng/ and NOD.Prf1/ mice.
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Autoantigen-Bearing APCs via Perforin
A subset of DC-killing memory T cells similar (but not identical) to
these CD44hiCD122+CD8+ cells has been described (Guarda
et al., 2007). Because IFN-g was necessary, but not sufficient,
for suppression and the memory-like CD8+ cells of 17.6a-8.3b-
TG mice expressed granzyme B (Figure S4K), we suspected
that suppression might also involve killing of APCs. In fact, the
PLNs (but not MLNs) of NRP-V7-Kd-NP-treated mice contained
fewer CD11c+ DCs than the PLNs of TUM-Kd-NP-treated
controls (Figure 5C).
In vitro, 17.6a-8.3b-CD122+CD8+ cells killed NRP-A7-pulsed
NOD DCs, but not islet b-cells, unless they expressed a CD86
transgene, suggesting a role for costimulation in their cytolytic576 Immunity 32, 568–580, April 23, 2010 ª2010 Elsevier Inc.activity (Figure S5A). Furthermore, NRP-A7-pulsed NOD B cells
or DCs were rapidly destroyed in diabetes-resistant 17.6a-
8.3b-TG hosts but spared in diabetes-prone 17.4a-8.3b-TG
mice (Figure 5D and Figure S5B). APC killing was antigen
specific (Figure 5D) and was both CD8+ and CD122+ T cell
dependent because it could be transferred with bulk, but not
CD8- or CD122-depleted, splenocytes (Figure 5E). Similar
results were obtained in pMHC-NP-treated NOD hosts: NRP-
V7-Kd- and MimA2-Db-NP-treated (but not untreated) NODmice
specifically eliminated cognate peptide-pulsed DCs in vivo
(Figure 5F).
We next asked if APC killing was perforin-dependent. As
shown in Figure 5G, whereas perforin (Prf1)-competent 17.6a-
8.3b-TGmice eliminated both Fas/ and Fas+/+ NRP-A7-pulsed
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Figure 7. Restoration of Normoglycemia in Diabetic NOD.HHD Mice with pHLA-NPs
(A) Average percentages ± SEM of circulating hIGRP265-273-A2Kb
+ or InsB10-18-A2Kb
+ CD8+ cells (minus FLU-MP58-66-A2Kb
+ cells) in hyperglycemic NOD.HHD
mice treated with FLU-MP58-66-A2Kb-, hIGRP265-273-A2Kb-, or InsB10-18-A2Kb-NPs after ten doses (n = 5, 7, and 5, respectively).
(B and C) Average blood glucose levels in newly diagnosed diabetic NOD.HHDmice treated with FLU-MP58-66-A2Kb, hIGRP265-273-A2Kb, or InsB10-18-A2Kb NPs
(n = 5, 8, and 7, respectively). Curves include all mice, diabetic and nondiabetic. Mice were euthanized when blood glucose levels were >27 mM.
See also Figure S6.
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Boosting Autoregulatory T Cells with pMHC-NPAPCs, their Prf1/ counterparts could not. The memory-like
CD8+ cells of thesemice also required perforin to suppress auto-
antigen cross-presentation in the PLNs (Figure 5I versus Fig-
ure 4F). Likewise, pMHC-NP-treated, Prf1/ NOD mice failed
to eliminate Fas+/+ NRP-A7-pulsed APCs in vivo (Figure 5H).
Thus, memory low-avidity autoregulatory CD8+ cells kill autoan-
tigen-loaded APCs via perforin.
TheAnti-T1D Activity of pMHC-NPs Requires IFN-g, IDO,
and Perforin
We then asked if the above mechanisms contributed to pMHC-
NP-induced reversal of T1D. We treated newly diabetic NOD
mice with NRP-V7-Kd-NPs and rat-IgG (control), IFNg mAb, or
s.c. implants of 1-MT. IFNgmAb and 1-MT abrogated the thera-
peutic effect of pMHC-NP (Figures 6A and 6C). Similar results
were obtained in diabetic NOD.Ifng/ mice (Figure 6B) that
did not respond to pMHC-NP therapy. To investigate the role
of APC killing, we screened NOD.Prf1/mice for hyperglycemia
and treated the few mice that developed diabetes with NRP-V7-
Kd-NP. Most mice (n = 5/7) remained hyperglycemic (Figure 6B).
Furthermore, naive CFSE-labeled 17.4a-8.3b-CD8+ cells prolif-
erated in the PLNs of mice that were refractory to pMHC-NP
therapy because of IFNg blockade or deficiency, IDO inhibition,
or Prf1-deficiency, but not in the PLNs of wild-type NOD mice
treated only with pMHC-NP (Figures 6D and 6E). Thus, pMHC-
NP-induced inhibition of autoantigen cross-presentation and
T1D require IFNg, IDO, and perforin.Effects of NPs Coated with Human T1D-Relevant pHLAs
in Humanized NOD Mice
The above results begged the question of whether the pMHC-NP
approach might be applicable to human T1D. We focused on
two human autoantigenic epitopes that are recognized, with
increased frequency, by peripheral blood CD8+ cells of HLA-
A2+ diabetic patients (reviewed in Tsai et al., 2008). One spans
residues 265–273 of hIGRP (identical to mIGRP265-273), and the
other spans residues 10–18 of the Insulin B chain.
We first enumerated the presence of these two CD8+ specific-
ities in islets of mB2m–/– NOD mice expressing an HLA-A2a1a2-
Kba3 transgene covalently linked to hb2m (NOD.HHDmice) using
pHLA-A2-Kb tetramers. These mice express HLA-A*0201 in
a murine MHC class I-deficient background, exclusively export
A*0201-restricted CD8+ cells, and spontaneously develop T1D.
Both specificities were found in the islets (and, to a lesser extent,
blood) of NOD.HHDmice, albeit at significantly different frequen-
cies:0.2%mINS10-18-A2Kb versus0.8% hIGRP265-273-A2Kb
tetramer+CD8+ cells (using Influenza virus matrix protein (Flu-
MP)58-66-A2Kb tetramer as negative control [Figure S6A]). Treat-
ment of prediabetic (Figure S6B) or newly diabetic NOD.HHD
mice (Figure 7A) for 5 weeks with hIGRP265-273-A2Kb- or
mINS10-18-A2Kb-coated NPs caused substantial expansions of
the circulating hIGRP265-273-A2Kb- or mINS10-18-A2Kb-reactive
CD8+ cell pools, respectively, compared to Flu-MP58-66-A2Kb-
NP-treated control mice. Treatment with Flu-MP58-66-A2Kb-
NPsdidnot increase the frequencyof Flu-MP58-66-A2Kb-reactiveImmunity 32, 568–580, April 23, 2010 ª2010 Elsevier Inc. 577
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Boosting Autoregulatory T Cells with pMHC-NPCD8+ cells, as expected (data not shown). Importantly, treatment
of hyperglycemic NOD.HHD mice with hIGRP265-273-A2Kb- and
mINS10-18-A2Kb-NP restored normoglycemia in 7/8 and 5/8
mice, respectively (Figures 7B and 7C and Figures S6D and
S6E). In contrast, 4/5 FLU-MP58-66-A2K
b-NP-treated mice pro-
gressed to frank hyperglycemia (Figures 7B and 7C and Fig-
ure S6C). Thus, NPs coated with human T1D-relevant pHLA
complexes restore normoglycema in humanized NOD mice.
Figure S7 provides a schematic overview of the paradigm on
which pMHC-NPs therapy is based.DISCUSSION
Conventional wisdom based on current knowledge argues that
vaccines operating on antigen-experienced lymphocytes would
be deleterious in the context of autoimmunity because they
would potentiate reactivity against self. Here, we show that
lymphocyte memory arising in a chronic organ-specific autoim-
mune disease (T1D) in response to repeated autoantigen expo-
sure consists largely of pools of low-avidity autoregulatory
CD8+ cells. These small pools of disease-driven, antigen-experi-
enced autoregulatory CD8+ cells function as a negative feed-
back regulatory loop that aims to counter disease progression
by inhibiting the activation of naive, pathogenic autoreactive
(cognate and noncognate) specificities via suppression of auto-
antigen-loaded APCs. We further show that suppression of
antigen presentation requires engagement of cognate pMHC
on the APCs and that it is mediated by at least two different
mechanisms: one that involves suppression of function in an
IFN-g- and IDO-dependent manner and another that involves
killing of the APC via perforin. Most importantly, we describe
a therapeutic approach that exploits this paradigm.
Becausehigh-avidity is usually associatedwith superior fitness
(Ohet al., 2004), itmayappear paradoxical that the antigen-expe-
rienced CD44hiCD122+CD8+ cells that mediate pMHC-NP-
induced suppression predominantly arise from low-avidity
precursors. It should be noted, however, that the autoreactive
T cell repertoire, unlike the case for its foreign antigen-specific
counterpart, predominantly consists of naive low-avidity T cell
clones (Jiang and Chess, 2009). Furthermore, in spontaneous
autoimmune diseases, unlike most foreign antigen-specific
immune responses, there is chronic autoantigenic persistence.
We propose that repeated, low-dose antigenic stimulation of
autoreactive T cells induces reactivation-induced cell death of
naive and effector high-avidity clones and differentiation of the
more prevalent low-avidity autoreactive clones into memory
autoregulatory T cells. This scenario is compatible with what
we know about effector and memory T cell formation in the
context of acute or persistent antigen exposure (Appay et al.,
2000; Barber et al., 2006; Lechner et al., 2000; Sprent and Tough,
2001; Williams et al., 2006; Zajac et al., 1998). This hypothesis
also accords with the notion that T cells receiving submaximal
activation signals are more prone to becoming memory cells
than short-lived effectors (Williams et al., 2006). We do not
imply that memory T cells only arise from low-avidity precursors.
Rather, we suggest that memory T cell generation in chronic
autoimmunity occurs more efficiently in the low-avidity T cell
pool.578 Immunity 32, 568–580, April 23, 2010 ª2010 Elsevier Inc.These memory-like autoregulatory CD8+ cells inhibit the
presentation of antigens to noncognate T cell specificities
in vitro and in vivo in an IFN-g-, IDO- and perforin-dependent
manner. Because IFN-g can trigger IDO competence and regu-
latory activity in DCs (Ju¨rgens et al., 2009), IFN-gmay operate, in
part, via IDO. Together, these data strongly suggest that these
pools of monospecific memory-like T cells that are expanded
by pMHC-NP therapy blunt polyclonal autoimmune responses
by suppressing the antigen-presenting function of and by
directly killing autoantigen-loaded APCs (presenting both
cognate and noncognate pMHCs simultaneously). It may seem
surprising that these memory-phenotype T cells spare b cells
while killing APCs. One possibility, supported by our in vitro
data, is that the cytolytic activity of these low-avidity memory
autoregulatory CD8+ cells is elicited only when costimulatory
molecules are engaged.
Two important characteristics of pMHC-nanovaccines based
on this paradigm are noteworthy. The first is that such nanovac-
cines exclusively expand preexisting (i.e., disease-generated)
autoantigen-experienced CD8+ cells and thuswould be inconse-
quential in healthy individuals. The second is that, in principle,
they can be engineered with any disease-relevant pMHC
complex, regardless of prevalence of the cognate T cell popula-
tion, provided that it is involved in the disease process. This inter-
pretation stems from two observations: that NPs coated with
a pMHC recognized by a prevalent autoreactive CD8+ subset
were as effective as those coated with a pMHC recognized by
an infrequent subset and that NPs coated with two different
human T1D-relevant, but subdominant, pHLA-A2 complexes
could restore normoglycemia in NOD.HHDmice. It is also worth
noting that there is an intriguing parallel between our observa-
tions in pMHC-NP-treated mice and the outcome of hOKT3g1
(Ala-Ala) therapy in human T1D patients. These patients have
increased percentages of CD8+ cells with in vitro regulatory
activity (Bisikirska et al., 2005) and increased percentages of
memory-like autoreactive CD8+ cells (Cernea and Herold,
2010). It is conceivable that these T cells correspond to the
memory-like autoregulatory CD8+ cells described herein.
In sum, we have shown that progression of T1D results in the
generation of pools of antidiabetogenic memory-like autoregula-
tory CD8+ T cells that can be expanded by systemic delivery
of pMHC-NPs. The unique properties of pMHC-coated NPs,
coupled with current knowledge of antigenic specificities of
autoreactive CD8+ cells in human T1D, make this nanovaccine
an attractive candidate for clinical testing. If the paradigm on
which this nanovaccine is based held true in other chronic auto-
immune diseases involving autoreactive CD8+ cells (Walter and
Santamaria, 2005) or is extended to autoregulatory CD4+
T cells, pMHC-nanovaccines might find general applicability in
autoimmunity.EXPERIMENTAL PROCEDURES
Mice
17.6a-8.3b-TGNODmicewere produced bymicroinjecting TCRab transgenes
into NOD zygotes. NOD.G6pc2K209A-F213A mice were produced using gene-
targeted CK35 ESCs and by backcrossing the targeted allele onto the NOD
background. These studies were approved by the institutional animal care
committee.
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pMHC-coated iron oxide NPswere prepared as described (Moore et al., 2004).
Cohorts of 4-week-old female mice were injected i.v. with 0.375–7.5 mg iron in
PBS every 2weeks until the 3rd injection and every 3weeks thereafter. Cohorts
of 10-week-old females were injected with 7.5 mg of NP i.v. twice a week for
5 week . Mice were killed at the onset of T1D or followed for 32 weeks. In other
experiments, mice with blood glucose > 11 mM for 2 days were treated i.v.
twice a week with pMHC-NP or pMHC tetramers (5 mg) until stably normogly-
cemic (for 4 weeks) or with CD3 mAb (5 mg) for 5 days. Other cohorts received
pMHC-NPs and rat-IgG or IFNgmAb (500 mg i.p. twice a week for 2 weeks, fol-
lowed by 200 mg/week for 3 weeks) or implanted s.c. with depots (23 175 mg)
of 1-MT.
Islet-Associated CD8+ T Cells
Islet-associated CD8+ cells were obtained by culturing islets in 0.5 U/ml
Takeda rIL-2 for 610 days. CD8+ responses (2 3 104) were assayed in
cultures with peptide-pulsed (10 mM) splenocytes (105) for 48 hr. For TCR
repertoire studies, cDNAs from sorted tetramer+ CD8+ cells were amplified
with Va17- and Ca-specific primers, cloned, and sequenced.
Cytokine Secretion and Proliferation
FACS-sorted T cells (23 104) were incubated with peptide-pulsed (1 mM) DCs
(104) for 48 hr. The 24 hr supernatants were assayed for IL-2 and IFN-g. The
cells were pulsedwith 1 mCi of [3H]-thymidine at 48 hr and harvested 24 hr later.
For cytokine-induced proliferation, CFSE-labeled splenic CD8+ cells (2 3 104)
were incubated with 100 ng/ml rhIL-2 or rmIL-15 for 4 days.
Real-Time RT-PCR
cDNA was amplified using mouse Immunology 384 StellArray qPCR plates
with SYBR Green. The data were analyzed using the Global Pattern Recogni-
tion analysis tool.
In Vitro Suppression
FACS-sorted CD8+ cells (2 3 104) were cultured with gp33- (1 mM) and/or
NRP-A7 or V7-pulsed (0.01–1 mM) DCs (104) for 24 hr, prior to the addition of
CFSE-labeled CD8+ cells (2 3 104). In other experiments, sorted CD8+ cells
(3 3 104) were cocultured with CFSE-labeled 8.3-CD8+ cells (3 3 104) in
wells coatedwith CD3 andCD28mAbs (3 mg/ml). CFSE dilution wasmeasured
after 48–72 hr. Sorted tetramer+CD8+ cells from pMHC-NP-treated mice were
activated with CD3 mAb (3 mg/ml) + rIL-2 for 72 hr and cultured with peptide-
pulsed DCs prior to adding reporter cells. Some cultures received rat-IgG,
rat anti-mIL-10, rat anti-mTGFb, or rat anti-mIFN-g (all at 10 mg/ml), 8-PST
(100 mM), 1-MT (200–400 mM), or IFN-g (5–20 ng/ml).
In Vivo Suppression of Cross-presentation
Sorted CD122+ and CD122– CD8+ cells were activated with NRP-A7-pulsed
(1 mM) DCs in IL-2 for 3 days. These cells (3.5–7.5 3 106) were injected into
8-week-old NOD mice; 24 hr later, the hosts received 15 3 106 CFSE-labeled
8.3-CD8+ cells. The PLN andMLNCD8+ cells were examined for CFSE dilution
on day 6. In other experiments, we compared proliferation of transfusedCFSE-
labeled 17.4a-8.3b-CD8+ cells in untreated versus pMHC-NP-treated mice.
In Vivo Cytotoxicity
Purified splenic B cells or DCs were pulsed with peptides (0.01–10 mM)
for >2 hr at 37C. TUM-pulsed cells were labeled with 2 mM PKH26, and
NRP-A7, V7, or MimA2-pulsed cells with 0.1 mM CFSE. Alternatively, they
were labeled with CFSE (TUM, 3 mM CFSE; NRP-A7, 0.3 mM CFSE) for 3 min
at 37C. After washing, they were mixed 1:1 and injected i.v. (107) into TCR-
TG- or pMHC-NP-treated mice. The ratios of CFSE+ versus PKH26+ or CFSEhi
versus CFSElow B cells or DCs in the host spleen were measured after 18 hr.
For in vivo cytotoxicity assays in NOD.scid hosts, mice were transfused with
7–10 3 107 nondepleted, or CD8- or CD122-depleted splenic cells from
17.6a-8.3b-NOD.Tcra–/– mice. Target cells were injected 24 hr later, and
survival was assessed after 18 hr.
Transfer of Suppression
Splenic CD8+ or CD4+ cells from 50-week-old nondiabetic untreated mice or
pMHC-NP-cured animals (5 3 106) or TCR-TG mice (107) were transfusedi.v. into 5- to 10-week-old NOD.scid females. After 24 hr, the hosts received
2 3 107 pooled CD4+ and CD8+ splenocytes from 8- to 9-week-old female
NOD mice. Diabetes was monitored for 100 days. Some cohorts received
cognate pMHC-NPs (i.v., twice/week) after T cell transfer.
Statistical Analyses
Data were compared by Student’s t, Mann-Whitney U, Chi-Square, or two-
way ANOVA tests.
Additional Experimental Procedures
An expanded version of this section is provided in Supplemental Information.
SUPPLEMENTAL INFORMATION
The Supplemental Information includes seven figures and Supplemental
Experimental Procedures and can be found with this article online at doi:10.
1016/j.immuni.2010.03.015.
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